Looks like it could be any time for a announcement on the sale EKG products in the USA. The consultant has been providing their services for this to happen since October 1, 2014. Read between the lines, the hints are there from Cardiocomm.
Toronto, Ontario--(Newsfile Corp. - January 20, 2015) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm Solutions" or the "Company") today announced that it has entered into a sales and marketing agreement for growing and managing the Company's HeartCheck™ ECG related business in drug chains, mass retailers, club retailers, grocery retailers and distributors' head offices in the USA.
Under the five year agreement, CardioComm Solutions will issue 375,000 common shares to the consulting group ("Consultant") for $18,750 of services provided by Consultant between October 1, 2014 and December 31, 2014, and will issue an additional $15,000 of common shares of the Company for services to be provided from January 1, 2015 to March 31, 2015at a price per share equal to the greater of $0.05 or the closing price of the shares on the TSX Venture Exchange on March 31, 2015, whichever is greater. Any issuances of common shares of the Company are subject to the approval of the TSX Venture Exchange and applicable securities laws. After March 31, 2015, the Consultant will be provided commission based fees generated from the sales of HeartCheck™ ECG devices and recurrent SMART Monitoring ECG services use.
The USA retail pharmacy agreement was executed following the completion of pre-set Canadian retail pharmacy milestones.
For more about the Company's HeartCheck™ products and services and retail pharmacy sales can be seen at www.theheartcheck.com.
Read more at https://www.stockhouse.com/news/press-releases/2015/01/20/cardiocomm-solutions-announces-heartcheck-tm-ecg-pen-us-retail-pharmacy#yPLyocma0dwDCxfx.99